Incidence of infusion hypersensitivity reaction after withholding dexamethasone premedication in early breast cancer patients not experiencing two previous cycles of infusion hypersensitivity reaction for weekly paclitaxel chemotherapy
- 12 February 2018
- journal article
- research article
- Published by Springer Science and Business Media LLC in Supportive Care in Cancer
- Vol. 26 (7), 2471-2477
- https://doi.org/10.1007/s00520-018-4087-3
Abstract
Premedication with dexamethasone is an essential part of the prevention of hypersensitivity reaction (HSR) associated with taxane administration. However, the possibility of stopping dexamethasone premedication has been investigated in previous studies to reduce the steroid’s adverse events; however, either the result or the particular protocol was limited. Thus, our study aimed to evaluate the incidence of HSR after dexamethasone premedication discontinuation after lack of HSR in two previous weekly paclitaxel infusions.This publication has 20 references indexed in Scilit:
- Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reactionSupportive Care in Cancer, 2014
- A Search for Predictive Factors for Hypersensitivity Reactions to Paclitaxel and Platinum Salts in Chemotherapy for Gynecologic Pelvic NeoplasmsGynecologic and Obstetric Investigation, 2012
- Feasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reactionSupportive Care in Cancer, 2011
- Retrospective evaluation of weekly paclitaxel hypersensitivity reactions reported utilizing an electronic medical record system at a tertiary cancer centerSupportive Care in Cancer, 2009
- Tapering and Discontinuation of Glucocorticoid Prophylaxis during Prolonged Weekly to Biweekly Paclitaxel AdministrationChemotherapy, 2005
- Incidence and risk factors for paclitaxel hypersensitivity during ovarian cancer chemotherapyCancer Chemotherapy and Pharmacology, 2005
- Paclitaxel Plus Carboplatin Versus Gemcitabine Plus Paclitaxel in Advanced Non–Small-Cell Lung Cancer: A Phase III Randomized TrialJournal of Clinical Oncology, 2002
- Premedication Strategy for Weekly PaclitaxelCancer Investigation, 2002
- Single-Dose Dexamethasone Paclitaxel PremedicationGynecologic Oncology, 1998
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerThe New England Journal of Medicine, 1996